FDA’s Decision on Vonoprazan Delayed Due to Nitrosamine Impurity
The FDA has established an acceptable daily intake limit for NVP of 96ng/day.
Diagnosis & Disease Information
Weekly Dupilumab Beneficial in Eosinophilic Esophagitis
More patients receiving dupilumab have histologic remission, improvement in Dysphagia Symptom Questionnaire scores
Lirentelimab Efficacious, Safe for Patients With Eosinophilic Esophagitis
The first group received high-dose lirentelimab for 24 weeks. The second group received low-dose lirentelimab, while the placebo group received 6 monthly infusions during the 24-week study.
Mixed Results for Benralizumab in Eosinophilic Esophagitis Trial
The MESSINA study included patients 12 to 65 years of age with symptomatic and histologically active EoE.
Dupilumab Safely Improves EoE Symptoms, Regardless of Prior Corticosteroid Use
Among the dupilumab treatment and placebo groups, 69% and 71% had previously used STCs, respectively.
MPR Weekly Dose Podcast #124
Emergency Use authorization for Novavax vaccine; the Pfizer-BioNTech vaccine gains adolescent approval; submission for oral contraceptive to be switched to over the counter; Astepro nasal spray gets over-the-counter approval; and Dupixent shows benefits in pediatric patients with eosinophilic esophagitis.
Dupilumab Demonstrates Benefit in Pediatric Eosinophilic Esophagitis Trial
The phase 3 EoE KIDS study included 102 children with active eosinophilic esophagitis based on histologic improvement meeting validated histologic criteria.
May 2022: Drug Pipeline Updates
Stay up-to-date on the latest drugs in development.
MPR Weekly Dose Podcast Episode 117
The latest guidance for COVID-19 treatment Paxlovid following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; COVID-19 vaccine efficacy update for those aged under 5; And the latest on Monkeypox.
